Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPT-330 in Relapsed Childhood ALL and AML
NCT02091245Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), mixed lineage leukemia (MLL) and 2 more, sponsored by Dana-Farber Cancer Institute. Primary endpoints: Toxicity profile of KPT-330 assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 at 3 years and Maximum tolerated dose (MTD) of KPT-330 at 2 years. Started Mar 2014; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)mixed lineage leukemia (MLL)mixed phenotype acute leukemia (MPAL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02091245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091245.